In today’s marketplace, pharmaceutical and biotechnology companies are experiencing intense pricing, political, regulatory and market pressures. These forces are creating stress on the industry’s fundamental business model. Consequently, pharmaceutical and biotechnology companies must evaluate the optimal levels of human and capital investment in the commercial enterprise to ensure health and competitiveness.
Due to increasing prices and shrinking margin pressures, few, if any, companies can ignore how many people they staff to critical functions. Best Practices, LLC’s benchmarking study analyzes resource allocation specific to key business functions in the pharmaceutical and biotechnology industries and can further assist business unit managers in assessing their level of staffing investment and resources channeled into different business functions.
A sample of analyzed functions in the report is:
- Marketing – this is further segmented, analyzed, and benchmarked on the basis of product
- State Government Affairs - benchmarking data segmented by sales revenues provide greater insight and highlights trends
- Finance – segmented and benchmarked by sales revenues to provide greater insight and trends
If you have to defend or validate budget and staffing resource decisions, the Best Practices Pharmaceutical Budget and Staffing Benchmark Guide will prove invaluable. The rich metrics contained in this comprehensive report emanate from survey responses from staffing executives at such elite pharmaceutical and biotech companies as Abbott Labs, AstraZeneca, Bristol-Myers Squibb, J&J, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.